(International Print/Online Journal)

SJIF IMPACT FACTOR: 6.829
PUBMED-National Library of Medicine ID-101739732

ISSN (Print): 2209-2870
ISSN (Online): 2209-2862

International Journal of Medical Science and Current Research (IJMSCR)
Available online at: www.ijmscr.com
Volume 9, Issue 2 , Page No: 333-336
March-April 2026

IJMSCR

Field Cancerization in Oral Squamous Cell Carcinoma: An Overview of Molecular Markers and Detection Techniques

Rama Sharma,Nutan Tyagi, Akansha Misra, Nazifa Javaid, Navratna Singh, Prashant Kumar
Department of Oral Pathology and Microbiology,
Institute of Dental Studies and Technologies, Modinagar, India

***Corresponding Author:**

Rama Sharma
Postgraduate Resident, Department of Oral Pathology and Microbiology,
Institute of Dental Studies and Technologies, Modinagar, India

Type of Publication: Review Article

Conflicts of Interest: Nil

Abstract

Field cancerization refers to the presence of genetically altered cells in a region surrounding a primary tumor, predisposing the area to the development of multiple malignancies. This phenomenon is crucial in understanding oral squamous cell carcinoma (OSCC) and its recurrent nature. This review explores the concept of field cancerization, highlighting key molecular and genetic markers, detection methods, and implications for cancer diagnosis and prevention. Advances in the detection of pre-malignant fields offer significant potential for early intervention, improving prognosis and survival rates in OSCC. Overall, this review reinforces the significance of field cancerization in improving clinical outcomes in OSCC.

Keywords: Oral squamous cell carcinoma, Field Cancerization, Epithelial-mesenchymal transition

Introduction

Oral squamous cell carcinoma (OSCC) is among the most common malignancies of the head and neck, often presenting as a multifocal disease due to "field cancerization." First introduced by Slaughter in 1953, the concept of field cancerization suggests that a broad area surrounding a primary tumor contains genetically altered cells. These cells may undergo further mutations, leading to synchronous or metachronous tumors.[1,2] Understanding field cancerization is essential for early diagnosis, risk assessment, and effective therapeutic intervention.

Despite significant advancements in the understanding and management of OSCC, recurrence rates remain high, and patient outcomes are often compromised by the presence of undetected pre-malignant fields surrounding the primary lesion. Current diagnostic protocols primarily focus on clinically evident tumors, often overlooking the molecularly altered fields that predispose to secondary malignancies. This review was undertaken to consolidate current knowledge on the concept of field cancerization in OSCC, emphasizing the emerging molecular markers and detection techniques that hold promise for early identification of high-risk areas. By providing an updated overview of these biomarkers and technologies, this review aims to support improved diagnostic strategies, personalized treatment planning, and preventive approaches in the management of oral cancer.

Mechanisms Underlying Field Cancerization

Field cancerization involves a sequence of genetic and epigenetic events within a population of epithelial cells, predisposing them to malignant transformation. Key processes include:

1. Genomic Instability: Loss of heterozygosity (LOH), microsatellite instability, and DNA aneuploidy are common early indicators.
2. Clonal Expansion and Mutation Accumulation: Pre-malignant cells undergo clonal proliferation, with successive mutations contributing to a malignant phenotype.
3. Tumor Microenvironment and EMT: Epithelial-mesenchymal transition (EMT) and interactions with stromal cells, like myofibroblasts, facilitate invasiveness and metastasis.[3]

Molecular Markers in Field Cancerization

Field cancerization in OSCC is characterized by specific genetic, epigenetic, and protein markers, which can serve as diagnostic and prognostic indicators. These biomarkers can be grouped as follows:

1. Genetic and Chromosomal Alterations

- Loss of Heterozygosity (LOH) and Microsatellite Alterations: LOH at various loci is commonly detected in pre-malignant and malignant fields. Microsatellite instability further indicates chromosomal instability, a hallmark of early carcinogenesis.
- p53 Mutations: The p53 gene, often termed the "guardian of the genome," is a tumor suppressor frequently mutated in OSCC.
- DNA Aneuploidy and Chromosomal Aberrations: Changes in DNA content, including aneuploidy and specific chromosomal gains or losses, can be detected by flow cytometry or array comparative genomic hybridization.

2. Protein and Cellular Markers

- Proliferation Markers (e.g., Ki-67): Ki-67 indicates cellular proliferation, reflecting the aggressive potential of altered fields.
- Cytokeratins and Epithelial Markers (e.g., TPA, TPS): Tissue polypeptide antigen (TPA) and tissue polypeptide-specific antigen (TPS) mark epithelial proliferation in pre-cancerous lesions.
- Stem Cell Markers (e.g., Oct4, Sox2): These markers highlight stem cell-like properties within altered cells, contributing to tumor progression.

3. Epigenetic and Regulatory Markers

- MicroRNAs (miRNAs): Specific miRNAs, such as hsa-miR-221 and hsa-miR-21, regulate gene expression, playing roles in cell cycle control and apoptosis.
- Epigenetic Modifications: Methylation of genes like MutL protein homolog 1 and methylguanine-methyltransferase is common in early cancer fields.

4. Other Biomarkers

   1. Inflammation-Related Markers (e.g., IL-17A): IL-17A and other cytokines are involved in cancer-related inflammation, which can promote tumor growth.
   2. Extracellular Matrix Modulators (e.g., MMP-9, TIMP-1): Matrix metalloproteinase 9 (MMP-9) and its inhibitor (TIMP-1) modulate the extracellular matrix, aiding in cellular invasion.[4]

Detection Techniques for Field Cancerization

Advances in molecular and imaging techniques have enhanced the detection of field cancerization, enabling early identification of high-risk areas in the oral mucosa. Key techniques include:

1. Polymerase Chain Reaction (PCR) and Immunohistochemistry (IHC): PCR is widely used to detect genetic mutations (e.g., p53) and LOH. IHC can visualize specific protein markers like Ki-67 and cytokeratins in tissue sections.
2. Genomic and Proteomic Profiling:

Volume 9, Issue 2; March-April 2026; Page No 333-336

3. Flow Cytometry and Comparative Genomic Hybridization: High-resolution flow cytometry enables the quantification of DNA aneuploidy, while comparative genomic hybridization reveals chromosomal aberrations.
4. Liquid Biopsy: An emerging tool, liquid biopsy, analyzes circulating DNA, RNA, and proteins, offering a non-invasive method for early detection and monitoring.[5]

Clinical Implications

The identification of field cancerization markers is valuable in managing OSCC, as it helps in:

1. Early Diagnosis and Monitoring: Biomarkers in pre-cancerous fields allow for earlier intervention, potentially halting cancer progression.
2. Personalized Treatment Planning: Detection of specific molecular alterations can guide targeted therapies and predict treatment responses.
3. Preventing Recurrence: Monitoring field cancerization can reduce recurrence risk by addressing genetically altered fields beyond the primary lesion.[6]

Future Perspectives

Research in field cancerization continues to evolve, focusing on integrating molecular markers with clinical diagnostics. Advances in liquid biopsy, single-cell sequencing, and proteomics may further enable real-time, non-invasive monitoring of high-risk fields. Future studies on the tumor microenvironment and the role of immunomodulatory factors in field cancerization will also enhance our understanding of OSCC progression.

Emerging Molecular Markers

1. CASP8 Mutations: A 2024 study identified CASP8 gene mutations, particularly the p.S375F variant, as early events in the development of field cancerization.[7] These mutations are associated with immune evasion and increased tumor cell migration, suggesting their potential as early biomarkers for OSCC progression.
2. DNA Methylation Patterns: Aberrant methylation of genes such as MGMT, APC, TIMP3, RAR, ECAD, and p16 has been detected not only in tumor tissues but also in adjacent noncancerous tissues. This "epigenetic field defect" indicates that DNA methylation profiling could serve as a predictive tool for cancer risk assessment.[8]
3. MicroRNAs (miRNAs): Specific miRNAs, including miR-196a, miR-196b, miR-155, miR-21, and miR-424, have been found to be upregulated in OSCC, while others like miR-345, miR-101, miR-144, and miR-204 are downregulated. These miRNAs are involved in regulating cell proliferation, apoptosis, and metastasis, making them potential biomarkers for disease progression.[9]

Advanced Detection Techniques

1. Liquid Biopsy: This minimally invasive technique involves analyzing circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and miRNAs in bodily fluids like blood and saliva. Liquid biopsy has shown promise in early detection, monitoring treatment response, and identifying minimal residual disease in OSCC patients.[10]
2. Lab-on-a-Chip (LOC) Devices: LOC systems integrate multiple laboratory functions on a single chip, enabling rapid and automated analysis of biomarkers from small sample volumes. These devices can detect specific proteins and nucleic acids, facilitating point-of-care diagnostics for OSCC[11]
3. Artificial Intelligence (AI) and Deep Learning: AI algorithms, particularly deep learning models like EfficientNetB3, have demonstrated high accuracy in analyzing medical images for OSCC detection. These technologies can assist in early diagnosis and personalized treatment planning by identifying subtle patterns indicative of field cancerization.[12,13,14]

Conclusion

Field cancerization in OSCC involves a complex interplay of genetic, epigenetic, and environmental factors, leading to the development of genetically altered fields predisposed to malignancy. The identification of molecular markers and the application of advanced detection techniques offer significant potential for early diagnosis, personalized treatment, and improved outcomes. As our knowledge of field cancerization deepens, it will contribute to more effective and preventative approaches in the fight against oral cancer.Recent advancements in the study of field cancerization in oral squamous cell carcinoma (OSCC) have introduced novel molecular markers and detection techniques, enhancing our understanding and management of the disease

References

1. Slaughter, D. P., Southwick, H. W., & Smejkal, W. (1953). "Field cancerization" in oral stratified squamous epithelium. *Cancer*, 6(5), 963-968.
2. Brennan, J. A., Mao, L., Hruban, R. H., et al. (1995). Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. *New England Journal of Medicine*, 332(7), 429-435.
3. Califano, J., van der Riet, P., Westra, W., et al. (1996). Genetic progression model for head and neck cancer: Implications for field cancerization. *Cancer Research*, 56(11), 2488-2492.
4. Cruz, I., Snijders, P. J., van Houten, V. M., et al. (2002). Specific p53 gene mutations identified by fluorescence in situ hybridization in oral pre-malignant lesions predict malignant progression. *Journal of Clinical Pathology*, 55(8), 602-607.
5. Warnakulasuriya, S. (2009). Global epidemiology of oral and oropharyngeal cancer. *Oral Oncology*, 45(4-5), 309-316.
6. Schepman, K. P., van der Meij, E. H., Smeele, L. E., & van der Waal, I. (1998). Malignant transformation of oral leukoplakia: A follow-up study of a hospital-based population of 166 patients with oral leukoplakia. *Oral Oncology*, 34(6), 461-467.
7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium. *Cancer*. 1953;6(5):963-968
8. Samantaray S, Panda CK. Molecular biomarkers in oral cancer: A review. *Cancers of the Head & Neck*. 2016;1:1.
9. Sannigrahi MK, et al. Oral field cancerization: Tracking the invisible. *International Journal of Oral Health Sciences*. 2019;9(1):1-7.
10. Singh AK, et al. Decoding the molecular landscape of field cancerization in oral cancer: Current evidence and future directions. *Human Genomics*. 2024;18(1):
11. ulasinghe A, et al. Liquid biopsy in oral cancer: Current status and future perspectives. *Biomedicines*. 2021;9(10):1478. 8
12. Wang J, et al. Emerging trends of microRNAs in oral squamous cell carcinoma: A systematic review. *Cancers*. 2024;16(4):601.
13. Alabi RO, et al. Artificial intelligence-driven models for early detection of oral squamous cell carcinoma using histopathological images. *arXiv*. 2024.
14. Sharma A, et al. Lab-on-a-chip platforms in oral cancer diagnostics: Current landscape and future perspectives. *Diagnostics*. 2021;11(7):1287.

Volume 9, Issue 2; March-April 2026; Page No 333-336